Recurrent or residual adenomas are frequently treated with Gamma Knife radiosurgery (GKRS). The most common complication after GKRS for pituitary adenomas is hypopituitarism. In the current study, the authors detail the timing and types of hypopituitarism in a multicenter, international cohort of pituitary adenoma patients treated with GKRS.
Seventeen institutions pooled clinical data obtained from pituitary adenoma patients who were treated with GKRS from 1988 to 2016. Patients who had undergone prior radiotherapy were excluded. A total of 1023 patients met the study inclusion criteria. The treated lesions included 410 nonfunctioning pituitary adenomas (NFPAs), 262 cases of Cushing’s disease (CD), and 251 cases of acromegaly. The median follow-up was 51 months (range 6–246 months). Statistical analysis was performed using a Cox proportional hazards model to evaluate factors associated with the development of new-onset hypopituitarism.
At last follow-up, 248 patients had developed new pituitary hormone deficiency (86 with NFPA, 66 with CD, and 96 with acromegaly). Among these patients, 150 (60.5%) had single and 98 (39.5%) had multiple hormone deficiencies. New hormonal changes included 82 cortisol (21.6%), 135 thyrotropin (35.6%), 92 gonadotropin (24.3%), 59 growth hormone (15.6%), and 11 vasopressin (2.9%) deficiencies. The actuarial 1-year, 3-year, 5-year, 7-year, and 10-year rates of hypopituitarism were 7.8%, 16.2%, 22.4%, 27.5%, and 31.3%, respectively. The median time to hypopituitarism onset was 39 months.
In univariate analyses, an increased rate of new-onset hypopituitarism was significantly associated with a lower isodose line (p = 0.006, HR = 8.695), whole sellar targeting (p = 0.033, HR = 1.452), and treatment of a functional pituitary adenoma as compared with an NFPA (p = 0.008, HR = 1.510). In multivariate analyses, only a lower isodose line was found to be an independent predictor of new-onset hypopituitarism (p = 0.001, HR = 1.38).
Hypopituitarism remains the most common unintended effect of GKRS for a pituitary adenoma. Treating the target volume at an isodose line of 50% or greater and avoiding whole-sellar radiosurgery, unless necessary, will likely mitigate the risk of post-GKRS hypopituitarism. Follow-up of these patients is required to detect and treat latent endocrinopathies.
Correspondence Jason P. Sheehan: University of Virginia Health System, Charlottesville, VA. email@example.com.
INCLUDE WHEN CITING Published online November 9, 2018; DOI: 10.3171/2018.5.JNS18509.
Disclosures Dr. Lunsford reports being a consultant for Insightec DSMB and having direct stock ownership in Elekta. Dr. Grills reports having direct stock ownership in Greater Michigan Gamma Knife, where she is on the executive board of directors, and she reports receiving, through her institution, research funding from Elekta that is unrelated to the present study.
AhmedS, ElsheikhM, StrattonIM, PageRC, AdamsCB, WassJA: Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. 50:561–567, 199910.1046/j.1365-2265.1999.00760.x10468920)| false
FeiglGC, PistracherK, BergholdA, MokryM: Pituitary insufficiency as a side effect after radiosurgery for pituitary adenomas: the role of the hypothalamus. 113Suppl:153–159, 201010.3171/2010.8.GKS1095921222294)| false
MinnitiG, Jaffrain-ReaML, OstiM, CantoreG, EnriciRM: Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques. 30:167–176, 20071748397310.1007/s10143-007-0072-x)| false
NomikosP, LadarC, FahlbuschR, BuchfelderM: Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas—a study on 721 patients. 146:27–35, 200410.1007/s00701-003-0174-3)| false
PollockBENippoldtTBStaffordSLFooteRLAbboudCF: Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg97:525–5302002
SheehanJPNiranjanASheehanJMJaneJAJrLawsERKondziolkaD: Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg102:678–6912005
SheehanJP, NiranjanA, SheehanJM, JaneJAJr, LawsER, KondziolkaD, : Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. 102:678–691, 20051587151110.3171/jns.2005.102.4.0678)| false
SheehanJP, PouratianN, SteinerL, LawsER, VanceML: Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. 114:303–309, 201110.3171/2010.5.JNS09163520540596)| false
ShiueK, BarnettGH, SuhJH, VogelbaumMA, ReddyCA, WeilRJ, : Using higher isodose lines for gamma knife treatment of 1 to 3 brain metastases is safe and effective. 74:360–366, 201410.1227/NEU.000000000000028924448185)| false
SnellJW, SheehanJ, StroilaM, SteinerL: Assessment of imaging studies used with radiosurgery: a volumetric algorithm and an estimation of its error. Technical note. 104:157–162, 20061650916110.3171/jns.2006.104.1.157)| false
WowraBStummerW: Efficacy of gamma knife radiosurgery for nonfunctioning pituitary adenomas: a quantitative follow up with magnetic resonance imaging-based volumetric analysis. J Neurosurg97 (5 Suppl):429–4322002
WowraB, StummerW: Efficacy of gamma knife radiosurgery for nonfunctioning pituitary adenomas: a quantitative follow up with magnetic resonance imaging-based volumetric analysis. 97 (5 Suppl):429–432, 200210.3171/jns.2002.97.supplement_5.042912507069)| false